Leading vaccine makers like Eli Lilly and Co. (NYSE: LLY), Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 pandemic, but now ...
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while Pfizer ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...
Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the ...
Pfizer, which on Monday acquired cancer drugmaker Medivation for $14 billion, has added to its portfolio yet again. The New York-based drugmaker will buy AstraZeneca’s small molecule antibiotics ...
The rumors are true. Pfizer offered to buy AstraZeneca for $76.62 per share, valuing the company around $100 billion. To put that in perspective, instead of buying AstraZeneca, Pfizer could buy these ...
AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from AbbVie ...
It is still too early to determine any definitive federal policies for 2025 (or beyond) that could affect these companies. However, some analysts have speculated that the administration might restrict ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback